Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Subjects With Select Advanced Malignancies

NCT02118337 is registered in ClinicalTrials.gov with MedImmune LLC as lead sponsor.

NCT NCT02118337
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02118337 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Subjects With Select Advanced Malignancies
Lead sponsor
MedImmune LLC
Phase
Phase 1/2
Overall status
Completed
Start date
May 19, 2014
Completion date
March 17, 2020
Enrollment
97 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

clear cell renal cell carcinoma, kidney cancer, select advanced malignancies